On the public citation graph
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Inferred edges come from two machine sources: sweeps of open repository
metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is
labelled with the one it came from. Neither is a complete citation index — absence here is not
evidence of absence.
1 of the 60 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1210/jc.2014-2739 (notice 2015-05-01).
Dataset join, best-effort; this page does not check the publisher record.
Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0);
dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated
CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.26156openalex-snapshotAssociation between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
inferredcites →https://doi.org/10.1002/hep.27981openalex-snapshotPresence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
inferredcites →https://doi.org/10.1002/hep.28985openalex-snapshotMetabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshotThe diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1002/hep.29489openalex-snapshotPerformance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.30670openalex-snapshotIncretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.1007/s00535-019-01626-1openalex-snapshotDiagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.diabet.2019.11.004openalex-snapshotScreening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
inferredcites →https://doi.org/10.1053/j.gastro.2019.01.042openalex-snapshotAccuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1111/dom.12973openalex-snapshotNon‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
inferredcites →https://doi.org/10.1111/jgh.14577openalex-snapshotScreening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
inferredcites →https://doi.org/10.1111/liv.12840openalex-snapshotClinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshotScreening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1136/gutjnl-2020-320622openalex-snapshotNAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
inferredcites →https://doi.org/10.1136/jim-2017-000554openalex-snapshotGlucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option
inferredcites →https://doi.org/10.1210/jc.2014-2739openalex-snapshotWITHDRAWN: High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (article published in final form as 10.1210/jc.2015-1966)
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshotHigh Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.2337/dc19-0167openalex-snapshotRole of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshotPerformance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshotEconomic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.2337/dc20-s004openalex-snapshot4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
inferredcites →https://doi.org/10.3390/jcm9041032openalex-snapshotScreening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience
inferredcites →https://doi.org/10.7326/m15-1774openalex-snapshotLong-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extractedThe Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.1002/hep.32244openalex-snapshotEffect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/hep4.1957openalex-snapshotInteraction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019
inferred← citeshttps://doi.org/10.1002/jgh3.12606openalex-snapshotPrevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes
inferred← citeshttps://doi.org/10.1002/jgh3.70039openalex-snapshotOverlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
inferred← citeshttps://doi.org/10.1002/jmv.28239openalex-snapshotDevelopment and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/oby.23263openalex-snapshotType 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/oby.24130openalex-snapshotObesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen
inferred← citeshttps://doi.org/10.1002/poh2.70032openalex-snapshotFactors Associated With Liver Fibrosis in Patients With Type 2 Diabetes and the Predictive Value of CHI3L1
inferred← citeshttps://doi.org/10.1007/s11606-025-09659-4openalex-snapshotDiagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Fibrosis in a Real-World Primary Care Setting: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.1007/s11892-024-01558-yopenalex-snapshotNAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1007/s13410-026-01633-yopenalex-snapshotImproving stratification of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease patients with type-2 diabetes mellitus in low-resource settings
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101142openalex-snapshotLower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
inferred← citeshttps://doi.org/10.1016/j.aohep.2024.101584openalex-snapshotFLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
inferred← citeshttps://doi.org/10.1016/j.bbadis.2023.166763openalex-snapshotThe evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.01.032openalex-snapshotThe Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.cgh.2025.02.018openalex-snapshotEffectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.clnu.2024.02.006openalex-snapshotNon-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002–2022)
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.109827openalex-snapshotPrevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111609openalex-snapshotThe hidden epidemic: Uncovering incidental fatty liver disease and its metabolic comorbidities by datamining in a hospital data lake – A real-world cohort study
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112418openalex-snapshotAssociation of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
inferred← citeshttps://doi.org/10.1016/j.diabres.2026.113240openalex-snapshotGestational diabetes and subsequent risk of type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in a commercially insured U.S. Pregnancy cohort
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshotAmerican Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.eprac.2025.04.021openalex-snapshotDiagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.11.010openalex-snapshotA prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.medj.2024.03.003openalex-snapshotLiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population
inferred← citeshttps://doi.org/10.1016/j.microc.2026.117763openalex-snapshotMolecular mechanism and metabolic abnormality detection of CYP2C19 based on electrochemical sensors: Metabolic driving factors of MASLD liver fibrosis
inferred← citeshttps://doi.org/10.1016/s2468-1253(23)00157-7openalex-snapshotType 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
inferred← citeshttps://doi.org/10.1016/s2468-1253(24)00313-3openalex-snapshotScreening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study
inferred← citeshttps://doi.org/10.1038/s41598-024-63386-0openalex-snapshotAssociations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study
inferred← citeshttps://doi.org/10.1039/d2mo00036aopenalex-snapshotMetabolomics study reveals the alteration of fatty acid oxidation in the hearts of diabetic mice by empagliflozin
inferred← citeshttps://doi.org/10.1053/j.gastro.2023.04.025openalex-snapshotFibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
inferred← citeshttps://doi.org/10.1053/j.gastro.2023.05.053openalex-snapshotPrevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
inferred← citeshttps://doi.org/10.1093/ajhp/zxaf251openalex-snapshotPharmacist-led screening for advanced fibrosis using the FIB-4 index in patients 65 years or older with a clinical suspicion for MASLD at a family medicine clinic
inferred← citeshttps://doi.org/10.1093/fampra/cmag008openalex-snapshotCan the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
inferred← citeshttps://doi.org/10.1097/js9.0000000000001872openalex-snapshotEffect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study
inferred← citeshttps://doi.org/10.1097/js9.0000000000002680openalex-snapshotIntegrated network toxicology and population-based analysis uncovers organophosphate flame retardant exposure as a risk factor for hepatic steatosis and fibrosis: mechanistic and clinical insights
inferred← citeshttps://doi.org/10.1097/md.0000000000042016openalex-snapshotThe accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease
inferred← citeshttps://doi.org/10.1111/1751-2980.13325openalex-snapshotType 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1111/apt.70020openalex-snapshotAddressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective
inferred← citeshttps://doi.org/10.1111/ctr.15437openalex-snapshotGraft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study
inferred← citeshttps://doi.org/10.1111/dme.14912openalex-snapshotBanting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’
inferred← citeshttps://doi.org/10.1111/dom.14651openalex-snapshotThe metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
inferred← citeshttps://doi.org/10.1111/dom.15758openalex-snapshotImpact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
inferred← citeshttps://doi.org/10.1111/dom.16065openalex-snapshotSimilar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
inferred← citeshttps://doi.org/10.1111/dom.70398openalex-snapshotSpatiotemporal burden, risk factors, and genetic causality of non‐alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi‐database analysis
inferred← citeshttps://doi.org/10.1111/dom.70820openalex-snapshotEffects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
inferred← citeshttps://doi.org/10.1111/jdi.70112openalex-snapshotA nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
inferred← citeshttps://doi.org/10.1111/jgh.16240openalex-snapshotEvaluation of blood‐based PRO‐C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jvh.13808openalex-snapshotA novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
inferred← citeshttps://doi.org/10.1111/liv.15259openalex-snapshotPrevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001466openalex-snapshotForns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study
inferred← citeshttps://doi.org/10.1136/bmjopen-2022-063959openalex-snapshotIdentification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-080549openalex-snapshotRisk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study
inferred← citeshttps://doi.org/10.1136/bmjopen-2024-087550openalex-snapshotPrevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China
inferred← citeshttps://doi.org/10.1136/gutjnl-2023-330269openalex-snapshotClinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial
inferred← citeshttps://doi.org/10.1148/radiol.250026openalex-snapshotLiver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
inferred← citeshttps://doi.org/10.1155/2022/8429847openalex-snapshotMetabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center
inferred← citeshttps://doi.org/10.1155/2023/3803056openalex-snapshotThe PTP1B Inhibitor Trodusquemine (MSI-1436) Improves Glucose Uptake in Equine Metabolic Syndrome Affected Liver through Anti-Inflammatory and Antifibrotic Activity
inferred← citeshttps://doi.org/10.1155/2024/8877130openalex-snapshotThe Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
inferred← citeshttps://doi.org/10.11569/wcjd.v33.i2.122openalex-snapshotPotential association of neutrophil-albumin ratio with non-alcoholic fatty liver disease: A cross-sectional study based on NHANES
inferred← citeshttps://doi.org/10.1159/000527595openalex-snapshotObesity-Induced Hepatic Steatosis Is Partly Mediated by Visceral Fat Accumulation in Subjects with Overweight/Obesity: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.1177/15578518251377780openalex-snapshotTriglyceride Glucose Index and Related Parameters Are Effective Biomarkers to Identify Metabolic Dysfunction-Associated Steatotic Liver Disease Among Egyptian Adults with Type 2 Diabetes
inferred← citeshttps://doi.org/10.1177/20503121241292678openalex-snapshotNon-alcoholic fatty liver disease among people living with HIV on long-term antiretroviral therapy in Indonesia: Prevalence and related factors
inferred← citeshttps://doi.org/10.1177/2633559x231213071openalex-snapshotPreventing and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 2 Diabetes: Promising Therapeutic Agents and Strategies
inferred← citeshttps://doi.org/10.1186/s12875-025-03039-xopenalex-snapshotPrevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors: a cross-sectional study in a primary care unit of a university hospital in Southern Thailand
inferred← citeshttps://doi.org/10.1186/s12876-022-02550-0openalex-snapshotAssociation between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12876-025-03612-9openalex-snapshotAssociation between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018
inferred← citeshttps://doi.org/10.1186/s12876-025-03850-xopenalex-snapshotMachine learning-based disease risk stratification and prediction of metabolic dysfunction-associated fatty liver disease using vibration-controlled transient elastography: Result from NHANES 2021–2023
inferred← citeshttps://doi.org/10.1186/s12876-025-03917-9openalex-snapshotGender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12913-022-07808-7openalex-snapshotImplementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12933-023-02049-2openalex-snapshotPlasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12944-025-02849-3openalex-snapshotAbnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic
inferred← citeshttps://doi.org/10.1186/s41043-026-01241-wopenalex-snapshotPilot study on the effectiveness of the traditional Karlovy Vary thermal spring drinking cure in the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD)
inferred← citeshttps://doi.org/10.1210/clinem/dgac382openalex-snapshotFibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID:
icsacinstitute.org/submit.